To add to its neurological disorders portfolio, Neurocrine has entered into a licensing agreement with BIAL for the development and commercialisation of the latter’s Parkinson’s disease asset, opicapone (Ongentys®). Neurocrine will pay an upfront payment of US$30 M and an additional US$115 M could be realized upon achieving certain development, regulatory, and commercial milestones. Opicapone, which has been approved in Europe as an adjunctive therapy, is differentiated from current catechol-O-methyltransferase (COMT) inhibitors by requiring only once-daily dosing.